Jagat Pharma, a trusted name in Ayurvedic wellness, is poised for remarkable growth as it targets revenue exceeding ₹250 crore by the financial year 2027.

Renowned for its expertise in Ayurvedic eye care and wellness products, the company has steadily expanded its reach across India and beyond, combining a legacy of over 42 years with innovative strategies.

The company has an impressive reach in the offline space also, with over 200 distributors across 17+ states. This includes a strong presence in South India with 50+ distributors for a territory that is embracing Ayurvedic solutions in increasing folds. 

With yearly 200% growth its online space dominance gives it a 60% market share in the Ayurvedic eye care segment as well. Jagat Pharma’s ambitious expansion plans extend far beyond Indian borders. The company is actively preparing to enter the lucrative markets of the Middle East and African countries, tapping into regions with a rising demand for holistic healthcare solutions.

A significant milestone in its international journey is its imminent entry into the United States, with exports slated to begin in December 2024. This step is backed by Jagat Pharma’s commitment to quality and compliance, as evidenced by its recent USFDA certification. Combined with its existing WHO-GMP certification, the company is well-positioned to meet the stringent global standards required to compete in international markets.

Domestically, Dr. Basu Group is increasing infrastructure growth by expanding its presence in metropolitan cities, including Mumbai, Noida Gurugram. It is a prudent move by the company to bring Ayurvedic solutions closer to the minds of people who are seeking natural alternatives for health and wellness in urban settings. In alignment with market needs, the infrastructure growth of Jagat Pharma aims to further solidify its leadership in the Ayurvedic wellness space.